Sorrento Therapeutics stock trades at USD 0.0004 amid liquidation

Sorrento Therapeutics stock stood at USD 0.0004 on OTC Markets on September 16, 2026, while its market capitalization was USD 220.51 thousand. The quote was 99.90 percent below the 52-week high of USD 0.42, putting the company at the extreme low end of its recent trading history.

Liquidation shapes the equity story

According to ElevenFlo on September 18, 2026, Sorrento's case is in post-effective-date liquidation. The confirmed plan became effective on April 10, 2024, and a liquidating trustee is administering unresolved claims and estate litigation.

That legal status changes how the quoted equity value should be read. The USD 220.51 thousand market capitalization is a trading measure for the remaining security, while the liquidation process governs claims against the estate and the distribution of any recoveries.

Price remains near the bottom

The USD 0.0004 quote on September 16, 2026, compares with a USD 0.42 52-week high. The 99.90 percent gap between those two values is the clearest numerical measure of the stock's long decline and leaves little room for ordinary operating metrics to define the market narrative.

Sorrento Therapeutics has operated as a biotechnology company, but the listed security now carries a separate legal and market context. For investors tracking the ticker, the key distinction is between a nominal OTC quotation and the value ultimately determined through the liquidation process.

OTC quote sets the reference

Sorrento Therapeutics stock stood at USD 0.0004 on OTC Markets on September 16, 2026. The same market snapshot placed capitalization at USD 220.51 thousand and the 52-week high at USD 0.42, making the liquidation status and estate administration central to interpreting the quotation.